Your allergy
What is allergy
House dust mite allergy
Pollen allergy
Living with allergy
Socio-economic impact
What is allergic asthma
How is allergy diagnosed
Treating allergy
Our solutions
Consumer healthcare
Diagnostics
Allergy vaccines
Production and quality
Emergency medicine
Our science
Scientific focus
Science & technology
Pipeline
Digital innovation
Collaboration & partnerships
Healthcare Professionals
Symposium on Specific Allergy
Henning Løwenstein Research Award
Our company
Press
Our strategy
Our leadership
Our history
Corporate governance
Sustainability
Environmental
Social
Governance
Investors
Overview
Financial reporting
Risk management
Reporting standards
Auditors
Governance
IR policy
Executive Leadership Team
Board of directors
News & Events
Company releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024
The Share
Dividend history
Analyst coverage
Analyst estimates
Shareholder information
Authorizations
ADR Programme
Contact IR
Annual general meeting
Annual general meeting (DK)
Capital Markets Day 2024
Careers
Current job opportunities
This is ALK
A culture of collaboration and inclusion
Meet your future colleagues
Meet our leaders
Select country
Fulltext search
Search
neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada
Link
https://www.globenewswire.com/news-release/2026/04/15/3274254/0/en/neffy-approv…
Created date
Wed, 04/15/2026 - 12:00
Nasdaq ID
3274254
Last updated:
15.04.2026
